Literature DB >> 14693543

Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study.

Sang-Oh Lee1, Nam Joong Kim, Sang-Ho Choi, Tae Hyong Kim, Jin-Won Chung, Jun-Hee Woo, Jiso Ryu, Yang Soo Kim.   

Abstract

Risk factors for the nosocomial occurrence of imipenem-resistant Acinetobacter baumannii (IRAB) were determined. A case-control study design was used for a comparison of two groups of A. baumannii-positive patients with control patients. Nosocomial IRAB was isolated from the first group of A. baumannii-positive patients, and imipenem-susceptible A. baumannii (ISAB) was isolated from the second group. The control patients were randomly selected in a 4:1 ratio from the same medical or surgical services from which the A. baumannii-positive patients were receiving care when the isolation of IRAB occurred. Risk factors analyzed included demographic variables, comorbid conditions, variables related to hospitalization, and the antimicrobials used. IRAB was isolated from 104 patients, and ISAB was isolated from 387 patients between January and December 2000. The risk factors for IRAB were a previous intensive care unit (ICU) stay (odds ratio [OR], 21.54; 95% confidence interval [CI], 10.73 to 43.23) and prior exposure to imipenem (OR, 9.18; 95% CI, 3.99 to 21.13) or third-generation cephalosporins (OR, 2.11; 95% CI, 1.13 to 3.95). Risk factors for ISAB were a previous ICU stay (OR, 8.05; 95% CI, 5.67 to 11.44) and exposure to third-generation cephalosporins (OR, 2.07; 95% CI, 1.47 to 2.91). Our results suggest that the nosocomial occurrence of IRAB or ISAB is strongly related to an ICU stay, and IRAB occurrence may be favored by the selection pressure of imipenem.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14693543      PMCID: PMC310160          DOI: 10.1128/AAC.48.1.224-228.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review.

Authors:  A D Harris; T B Karchmer; Y Carmeli; M H Samore
Journal:  Clin Infect Dis       Date:  2001-03-21       Impact factor: 9.079

2.  Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach.

Authors:  David L Paterson
Journal:  Clin Infect Dis       Date:  2002-05-23       Impact factor: 9.079

3.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Authors:  R A Deyo; D C Cherkin; M A Ciol
Journal:  J Clin Epidemiol       Date:  1992-06       Impact factor: 6.437

4.  Investigation of an outbreak of Acinetobacter calcoaceticus var. anitratus infections in an adult intensive care unit.

Authors:  J Contant; E Kemeny; C Oxley; E Perry; G Garber
Journal:  Am J Infect Control       Date:  1990-08       Impact factor: 2.918

5.  Epidemic bacteremia due to Acinetobacter baumannii in five intensive care units.

Authors:  C M Beck-Sagué; W R Jarvis; J H Brook; D H Culver; A Potts; E Gay; B W Shotts; B Hill; R L Anderson; M P Weinstein
Journal:  Am J Epidemiol       Date:  1990-10       Impact factor: 4.897

6.  Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli.

Authors:  Anthony D Harris; Matthew H Samore; Marc Lipsitch; Keith S Kaye; Eli Perencevich; Yehuda Carmeli
Journal:  Clin Infect Dis       Date:  2002-05-23       Impact factor: 9.079

7.  Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods.

Authors:  J Tankovic; P Legrand; G De Gatines; V Chemineau; C Brun-Buisson; J Duval
Journal:  J Clin Microbiol       Date:  1994-11       Impact factor: 5.948

8.  An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients.

Authors:  L Fierobe; J C Lucet; D Decré; C Muller-Serieys; A Deleuze; M L Joly-Guillou; J Mantz; J M Desmonts
Journal:  Infect Control Hosp Epidemiol       Date:  2001-01       Impact factor: 3.254

9.  Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis.

Authors:  O Lortholary; J Y Fagon; A B Hoi; M A Slama; J Pierre; P Giral; R Rosenzweig; L Gutmann; M Safar; J Acar
Journal:  Clin Infect Dis       Date:  1995-04       Impact factor: 9.079

10.  Nosocomial colonization and infection with multiresistant Acinetobacter baumannii: outbreak delineation using DNA macrorestriction analysis and PCR-fingerprinting.

Authors:  M J Struelens; E Carlier; N Maes; E Serruys; W G Quint; A van Belkum
Journal:  J Hosp Infect       Date:  1993-09       Impact factor: 3.926

View more
  43 in total

Review 1.  Management of antimicrobial use in the intensive care unit.

Authors:  Francisco Álvarez-Lerma; Santiago Grau
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

2.  Correlation between antibiotic consumption and resistance of bloodstream bacteria in a University Hospital in North Eastern Italy, 2008-2014.

Authors:  Marta Mascarello; Omar Simonetti; Anna Knezevich; Ludovica Ilaria Carniel; Jacopo Monticelli; Marina Busetti; Paolo Schincariol; Lucio Torelli; Roberto Luzzati
Journal:  Infection       Date:  2017-03-06       Impact factor: 3.553

Review 3.  Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.

Authors:  Yohei Doi; Gerald L Murray; Anton Y Peleg
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

4.  Mathematical model to quantify the effects of risk factors on carbapenem-resistant Acinetobacter baumannii.

Authors:  Michelle W Tan; David C Lye; Tat-Ming Ng; Michael Nikolaou; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

5.  Multi-drug-resistant gram-negative bacterial infection in surgical patients hospitalized in the ICU: a cohort study.

Authors:  V G Alexiou; A Michalopoulos; G C Makris; G Peppas; G Samonis; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-28       Impact factor: 3.267

6.  Clinical Features and Risk Factors for Development of Breakthrough Gram-Negative Bacteremia during Carbapenem Therapy.

Authors:  Ji-Yong Lee; Cheol-In Kang; Jae-Hoon Ko; Woo Joo Lee; Hye-Ri Seok; Ga Eun Park; Sun Young Cho; Young Eun Ha; Doo Ryeon Chung; Nam Yong Lee; Kyong Ran Peck; Jae-Hoon Song
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

7.  Time series analysis as a tool to predict the impact of antimicrobial restriction in antibiotic stewardship programs using the example of multidrug-resistant Pseudomonas aeruginosa.

Authors:  Matthias Willmann; Matthias Marschal; Florian Hölzl; Klaus Schröppel; Ingo B Autenrieth; Silke Peter
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

Review 8.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

9.  Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains.

Authors:  Jung-Jr Ye; Ching-Tai Huang; Shian-Sen Shie; Po-Yen Huang; Lin-Hui Su; Cheng-Hsun Chiu; Hsieh-Shong Leu; Ping-Cherng Chiang
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

Review 10.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.